In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), ...

Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock ...

Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial.

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radioligand ...

Actinium Pharmaceuticals (NYSE:ATNM) shares closed +21% higher on Monday after it reported positive data on its Iomab-B first-in-class targeted radiotherapy candidate for acute myeloid leukemia (AML).

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or ...

Find the latest Actinium Pharmaceuticals, Inc. ATNM analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

What Are Magnificent 7 Stocks? The Magnificent Seven has emerged as a replacement for FAANG stocks.